<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00015873</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068529</org_study_id>
    <secondary_id>ICU-INTERFANT99</secondary_id>
    <secondary_id>UKCCSG-LK-1999-05</secondary_id>
    <secondary_id>EU-20063</secondary_id>
    <secondary_id>EU-20588</secondary_id>
    <nct_id>NCT00015873</nct_id>
  </id_info>
  <brief_title>Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia</brief_title>
  <official_title>International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Childhood Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dutch Childhood Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining more than one drug may kill more cancer cells. It is
      not yet known which combination chemotherapy regimen is most effective for treating infants
      with acute lymphoblastic leukemia.

      PURPOSE: Randomized phase III trial to compare the effectiveness of different combination
      chemotherapy regimens in treating infants who have newly diagnosed acute lymphoblastic
      leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the outcome of induction chemotherapy followed by consolidation and
           reinduction chemotherapy with or without late intensification chemotherapy followed by a
           maintenance regimen or allogeneic bone marrow transplantation in infants with newly
           diagnosed acute lymphoblastic leukemia.

        -  Determine the value of a late intensification course between reinduction and maintenance
           therapy in these patients.

        -  Determine the prognostic value of age, immunophenotype, WBC, day 15 bone marrow status,
           and MLL gene rearrangement in patients treated with these regimens.

      OUTLINE: This is a partially randomized, multicenter study. Patients are stratified according
      to risk (high vs standard).

      Patients receive induction therapy comprising prednisone orally or IV three times a day on
      days 1-7; dexamethasone orally or IV three times a day on days 8-35; vincristine IV on days
      8, 16, 22, and 30; cytarabine IV over 30 minutes on days 8-21; daunorubicin IV over 60
      minutes on days 8 and 9; asparaginase IV over 1 hour or intramuscularly (IM) on days 15, 18,
      22, 25, 29, and 33; methotrexate intrathecally (IT) on days 1 and 29; and cytarabine IT on
      day 15. Patients receive prednisolone IT in combination with any dose of intrathecal
      chemotherapy. Patients with CNS involvement receive additional doses of methotrexate IT on
      days 8 and 22 and then weekly after day 29 until there is no evidence of CNS leukemia.

      After achieving complete remission, patients receive MARAM chemotherapy comprising oral
      mercaptopurine daily on days 1-14; methotrexate IV over 24 hours on days 1 and 8; leucovorin
      calcium orally or IV 36, 42, and 48 hours after beginning each dose of oral methotrexate;
      methotrexate IT on days 2 and 9; cytarabine IV over 3 hours twice daily on days 15, 16, 22,
      and 23; and asparaginase IV over 1 hour or IM on days 16 and 23. Patients receive
      prednisolone IT in combination with any dose of intrathecal methotrexate.

      At least 2 weeks after the completion of MARAM chemotherapy, patients receive OCTADD
      chemotherapy comprising oral dexamethasone three times a day on days 1-21; oral thioguanine
      daily on days 1-28 and 36-49; vincristine IV on days 2, 8, 16, and 22; daunorubicin IV over
      60 minutes on days 1, 8, 15, and 22; cytarabine IV on days 2-5, 9-12, 16-19, 23-26, 37-40,
      and 45-48; cytarabine IT on days 1 and 15; and cyclophosphamide IV over 1 hour on days 36 and
      49. Patients receive prednisolone IT in combination with any dose of intrathecal
      methotrexate.

      Patients are randomized to one of two treatment arms for late intensification therapy.

        -  Arm I: Beginning at least 1 week after the completion of OCTADD chemotherapy, patients
           receive VIMARAM chemotherapy comprising vincristine IV on days 1, 8, 15, and 22; oral
           mercaptopurine daily on days 1-14; methotrexate IV over 24 hours on days 1 and 8;
           leucovorin calcium orally or IV 36, 42, and 48 hours after the beginning of each dose of
           oral methotrexate; methotrexate IT on days 2 and 9; cytarabine IV over 3 hours twice
           daily on days 15, 16, 22, and 23; and asparaginase IV over 1 hour or IM on days 16 and
           23. Patients receive prednisolone IT in combination with any dose of intrathecal
           methotrexate. Patients then receive the appropriate maintenance therapy.

        -  Arm II: Patients do not receive VIMARAM chemotherapy but receive appropriate maintenance
           therapy.

      At least 2 weeks after the completion of the last course of chemotherapy, patients receive
      maintenance therapy. Patients with a good response to initial therapy with prednisone receive
      maintenance therapy comprising oral dexamethasone three times daily on weeks 1 and 2;
      vincristine IV on day 2 of weeks 1 and 2; oral mercaptopurine daily on weeks 1-14; and oral
      methotrexate once weekly on weeks 1-14.

      Patients with a poor response to initial therapy with prednisone receive maintenance therapy
      comprising oral mercaptopurine daily for weeks 1-14; oral methotrexate once weekly for weeks
      1-14; oral dexamethasone three times daily for weeks 1 and 2; vincristine IV on day 2 of
      weeks 1 and 2; etoposide IV over 2 hours once weekly on weeks 8 and 9; and cytarabine IV over
      1 hour once weekly on weeks 8 and 9.

      Treatment repeats in both maintenance therapy regimens every 14 weeks for a total of 3
      courses. Patients also receive methotrexate IT on day 1 of the first and third course of
      therapy and cytarabine IT on day 1 of the second course of therapy. Patients receive
      prednisolone IT in combination with any dose of intrathecal chemotherapy.

      Beginning after the completion of maintenance therapy, all patients receive continuing
      maintenance therapy comprising oral mercaptopurine daily and oral methotrexate once a week.
      Treatment continues until 104 weeks after initial diagnosis.

      Patients with a poor response to initial therapy with prednisone may receive allogeneic bone
      marrow transplantation if a donor is available. The patient undergoes transplantation
      immediately after OCTADD chemotherapy rather than being randomized and receiving maintenance
      therapy. These patients receive conditioning regimen comprising oral busulfan four times a
      day on days -8 to -5, etoposide IV over 4 hours on day -4, methotrexate IT on day -3, and
      cyclophosphamide IV over 1 hour on days -3 and -2. Allogenic bone marrow is transplanted on
      day 0. Patients then receive cyclosporine orally or IV on days 1-180 as graft-versus-host
      disease prophylaxis.

      Patients are followed annually.

      PROJECTED ACCRUAL: A total of 350 patients will be accrued for this study within 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1999</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival at 3-4 years after diagnosis</measure>
    <time_frame>4 years after diagnosis</time_frame>
    <description>Event-free survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>A no VIMARAM</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No VIMARAM preceding maintenance treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - VIMARAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCR i.v. 1.5 mg/m2/d - 4 days 6-MP p.o. 25 mg/m2/d - 15 days HD-MTX p.i.(24hr) 5 g/m2 - 2 days MTX + pred I.T. (age adapted) - 2 days HD-Ara-C p.i (3hr) 3 g/m2/12 hrs -8 days L-ASP p.i. (1hr) 5.000 U/m2 - 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase</intervention_name>
    <arm_group_label>B - VIMARAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <arm_group_label>B - VIMARAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
    <arm_group_label>B - VIMARAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>B - VIMARAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <arm_group_label>B - VIMARAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>B - VIMARAM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of acute lymphoblastic leukemia (ALL)

               -  Newly diagnosed

               -  Morphological verification by cytochemistry and immunophenotyping

          -  CNS or testicular leukemia at diagnosis allowed

          -  Trisomy 21 allowed

        PATIENT CHARACTERISTICS:

        Age:

          -  365 days or less

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy for leukemia

        Endocrine therapy:

          -  At least 4 weeks since prior systemic corticosteroids

          -  Prior inhaled steroids allowed

        Radiotherapy:

          -  No prior radiotherapy for leukemia

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Pieters, MD, MSC, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Erasmus MC - Sophia Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anna Children's Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Des Enfants Reine Fabiola</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children Crumlin</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale San Gerardo at University of Milano-Bicocca</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ostra Sjukhuset</name>
      <address>
        <city>Gothenburg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health at University of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester and Manchester Children's University Hospitals NHS Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital NHS Trust</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital for Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hempel G, Relling MV, de Rossi G, Stary J, De Lorenzo P, Valsecchi MG, Barisone E, Boos J, Pieters R. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer. 2010 Mar;54(3):355-60. doi: 10.1002/pbc.22266.</citation>
    <PMID>19731319</PMID>
  </results_reference>
  <results_reference>
    <citation>Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I, De Rossi G, Felice M, Lausen B, Leblanc T, Szczepanski T, Ferster A, Janka-Schaub G, Rubnitz J, Silverman LB, Stary J, Campbell M, Li CK, Suppiah R, Biondi A, Vora A, Valsecchi MG, Pieters R; Interfant-99 Study Group. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood. 2010 Oct 14;116(15):2644-50. doi: 10.1182/blood-2010-03-273532. Epub 2010 Jun 30.</citation>
    <PMID>20592248</PMID>
  </results_reference>
  <results_reference>
    <citation>Lönnerholm G, Valsecchi MG, De Lorenzo P, Schrappe M, Hovi L, Campbell M, Mann G, Janka-Schaub G, Li CK, Stary J, Hann I, Pieters R; Interfant-99 study group. Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009 May;52(5):596-601. doi: 10.1002/pbc.21925.</citation>
    <PMID>19132729</PMID>
  </results_reference>
  <results_reference>
    <citation>van der Linden MH, Valsecchi MG, De Lorenzo P, Möricke A, Janka G, Leblanc TM, Felice M, Biondi A, Campbell M, Hann I, Rubnitz JE, Stary J, Szczepanski T, Vora A, Ferster A, Hovi L, Silverman LB, Pieters R. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood. 2009 Oct 29;114(18):3764-8. doi: 10.1182/blood-2009-02-204214. Epub 2009 Aug 5.</citation>
    <PMID>19657114</PMID>
  </results_reference>
  <results_reference>
    <citation>Van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, Panzer-Grümayer ER, Schrappe M, Schrauder A, Meyer C, Marschalek R, Nigro LL, Metzler M, Basso G, Mann G, Den Boer ML, Biondi A, Pieters R, Van Dongen JJ; Interfant-99 Study Group. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia. 2009 Jun;23(6):1073-9. doi: 10.1038/leu.2009.17. Epub 2009 Feb 12.</citation>
    <PMID>19212338</PMID>
  </results_reference>
  <results_reference>
    <citation>Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, Janka G, Rubnitz J, Silverman L, Stary J, Campbell M, Li CK, Mann G, Suppiah R, Biondi A, Vora A, Valsecchi MG. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007 Jul 21;370(9583):240-50.</citation>
    <PMID>17658395</PMID>
  </results_reference>
  <results_reference>
    <citation>Pieters R, Schrappe M, de Lorenzo P, et al.: Outcome of infants less than one year of age with acute lymphoblastic leukemia treated with the Interfant-99 protocol. [Abstract] Blood 108 (11): A-145, 2006.</citation>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 14, 2014</last_update_submitted>
  <last_update_submitted_qc>February 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

